Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical Practice Guideline – Rare Endocrine Tumours

Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

ESMO Open 2024;9(10):103664
Hadoux J, Lamarca A, Grande E, et al., on behalf of the ESMO Guidelines Committee

  • This Clinical Practice Guideline provides key recommendations for managing rare endocrine tumours.
  • Neuroendocrine neoplasms of different origins, parathyroid carcinoma and intrathyroid thymic neoplasms are included.
  • The guideline covers clinical imaging and pathological diagnosis, staging and risk assessment, treatment and follow-up.
  • The authors comprise a multidisciplinary group of experts from different institutions and countries in Europe.
  • Recommendations are based on available scientific data and the authors’ collective expert opinion.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.